Genaissance Launches Second STRENGTH Study After Baycol Bails | GenomeWeb

NEW YORK, Oct. 18 - Genaissance Pharmaceuticals has launched a second version of its STRENGTH study after one drug from the original trial was taken off from the market after it was linked to patient deaths, the company said on Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.